$KDNY News
Last published 3y ago
- 3y agoKDNYChinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA NephropathyGlobeNewswireSEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoCWBREMANGHLKDNYMoore Kuehn Encourages CWBR, KDNY, GHL, and EMAN Investors to Contact Law FirmGlobeNewswireNEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoCWBRDMGHLKDNYMoore Kuehn Encourages CWBR, KDNY, GHL, and DM Investors to Contact Law FirmPR NewswireNEW YORK, July 17, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoKDNYChinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) CongressGlobeNewswireCHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysPharmacokinetics (PK) was well characterized with dose-proportional
- 3y agoKDNYNETINEXSURFMoore Kuehn Encourages NETI, SURF, KDNY, and NEX Investors to Contact Law FirmGlobeNewswireNEW YORK, June 16, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoCIRHMPTKDNYUSXMoore Kuehn Encourages KDNY, USX, CIR, and HMPT Investors to Contact Law FirmPR NewswireNEW YORK, June 13, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoKDNYChinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) CongressGlobeNewswireZigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria reductions in patients with
- 3y agoCCLNCLHRCLKDNY+7Stocks making the biggest moves midday: Carnival, Nasdaq, Oracle, KeyCorp and moreCNBCThese are the stocks posting the largest moves midday.
- 3y agoKDNYChinook Therapeutics Enters into Agreement to be Acquired by Novartis AGGlobeNewswireNovartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5
- 3y agoKDNYChinook Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmGlobeNewswireBOSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Chinook Therapeutics, Inc. (NASDAQ:KDNY) for potential securities law violations. Investors who have lost money in their Chinook
- 3y agoKDNYChinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney DiseaseGlobeNewswireSEATTLE, May 16, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and
- 3y agoKDNYChinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewswireSEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) CongressGlobeNewswireUpdated interim data to be presented from Cohort 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgANInitial data to be presented from the phase 1 study of CHK-336 in healthy volunteersAdditional
- 3y agoKDNYChinook Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSEATTLE , April 27, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of DirectorsGlobeNewswireSEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy VolunteersGlobeNewswireSEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSEATTLE, April 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics to Present at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease DaysGlobeNewswireSEATTLE, March 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023GlobeNewswireSEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewswireSEATTLE, March 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Announces Upcoming Presentations at the 5th Chronic Kidney Disease Drug Development SummitGlobeNewswireSEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdatesGlobeNewswireSEATTLE, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial OfficerGlobeNewswireSEATTLE, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics to Present at SVB Securities Global Biopharma ConferenceGlobeNewswireSEATTLE, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSEATTLE, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 3y agoKDNYChinook Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 4y agoKDNYChinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial ResultsGlobeNewswireSEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 4y agoKDNYChinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022GlobeNewswireThe initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductionsBION-1301 is well-tolerated, with no
- 4y agoKDNYChinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022GlobeNewswireAtrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12 weeks of treatment
- 4y agoKDNYChinook Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSEATTLE, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases,
- 4y agoKDNYChinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022GlobeNewswireUpdated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial Additional interim data to be presented from Cohorts 1 and 2 of the ongoing phase 1/2
- 4y agoKDNYChinook Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireSEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook manag
- 4y agoKDNYChinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewswireSEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update an
- 4y agoKDNYChinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSEATTLE, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensati
- 4y agoKDNYChinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022GlobeNewswireSEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook manage
- 4y agoKDNYChinook Therapeutics Announces Pricing of a $105 Million Public OfferingGlobeNewswireSEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share. In addition, and in
- 4y agoKDNYChinook Therapeutics Announces Proposed Public OfferingGlobeNewswireSEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it has commence
- 4y agoKDNYChinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022GlobeNewswireThe AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day despite maximal RAS inhibitor treatment, representing an IgAN patient population at high risk for progression
- 4y agoKDNYChinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022GlobeNewswireAll patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs) BION-1301 continues to demonstra
- 4y agoKDNYChinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensatio
- 4y agoKDNYChinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial ResultsGlobeNewswireSEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and
- 4y agoKDNYChinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) CongressGlobeNewswireData on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trial Updated data to be presented from Cohort 1 of Part 3 of the ongoing phase 1/2 study of BION-1301 in patients
- 4y agoKDNYChinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewswireSEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook manag
- 4y agoKDNYChinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat HyperoxaluriasGlobeNewswireSEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing has be
- 4y agoKDNYChinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare ConferenceGlobeNewswireSEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier
- 4y agoKDNYChinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support and Information to Help Reduce Barriers to Diagnosis and CareGlobeNewswireSEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative leveraging data and technology to drive awareness of Immunoglobulin A (IgA) ne